Patients in Stamford, Greenwich, Fairfield County, and throughout Connecticut can call 203-348-8805 to discuss whether GLP-1 therapy, semaglutide, tirzepatide, or another medically supervised weight-loss option may be appropriate
Although weight loss may be greater with tirzepatide, semaglutide has an indication for CV event reduction based on the SELECT trial, where the drug reduced the risk of MACE by 20% compared with standard care in patients with overweight/obesity and preexisting CVD
Weight Loss Smart, Medical, Sustainable Support Sexual Health Confidence & Connection Through Health Sexual wellness is closely tied to hormones, circulation, mental health, and overall physical wellbeing
All material is supplied for research use only
Asegrate de informar a tu mdico sobre tu historial clnico completo y cualquier otro tratamiento que ests tomando actualmente
Talk to your doctor today to see if this program could help you